Novo Nordisk: Haemophilia Foundation
The Novo Nordisk Haemophilia Foundation (NNHF) was created in 2005 to address the significant need to improve haemophilia treatment in developing countries, where it is not a healthcare priority and many patients go undiagnosed or are inadequately treated. Consequently, life expectancy for people with haemophilia is low and treatment with clotting factors is suboptimal. NNHF is an independent trust, located in Zurich, Switzerland, and funds programs to improve hemophilia care, treatment and awareness in the developing world. NNHF programs include awards, fellowships and development projects for patient education, doctor, nurse and laboratory staff training, as well as setting up diagnostic facilities and creating patient registries. NNHF works in developing or European transition countries where some haemophilia treatment is already present and can form the basis for sustainable projects. NNHF cooperates with partners in these countries, such as health ministries and other healthcare authorities or institutions, non-governmental and patient organisations, healthcare professionals and other foundations. Typical examples of NNHF programmes funding are: Awareness creation, Awards; Capacity building, Fellowships; Diagnosis & Registries. NNHF cooperates with partners in these countries, such as health ministries and authorities, non-governmental and patient organizations, health care professionals, other foundations and trusts.